Personalis (NASDAQ:PSNL) Reaches New 12-Month High - Here's What Happened

Key Points

• Personalis, Inc. (NASDAQ: PSNL) reached a new **52-week high** of $8.95 before closing at $8.49, with significant trading volume of **279,238 shares**.
• Wall Street analysts have mixed ratings on Personalis, with a consensus rating of **"Moderate Buy"** and a target price of **$7.42**, while Weiss Ratings maintains a **"sell (d-)"** rating.
• The company's recent earnings report showed it beating estimates with a loss per share of **($0.23)**, although revenue fell short of expectations at **$17.20 million**.

Shares of Personalis, Inc. (NASDAQ:PSNL - Get Free Report) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $8.95 and last traded at $8.49, with a volume of 279238 shares changing hands. The stock had previously closed at $8.22.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on PSNL. Wall Street Zen upgraded Personalis from a "sell" rating to a "hold" rating in a research report on Saturday, September 20th. Weiss Ratings restated a "sell (d-)" rating on shares of Personalis in a research report on Wednesday, October 8th. BTIG Research set a $6.00 price target on Personalis in a research report on Wednesday, August 6th. Finally, HC Wainwright reiterated a "buy" rating and issued a $8.50 price objective on shares of Personalis in a research report on Monday, September 8th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Personalis has a consensus rating of "Moderate Buy" and a consensus target price of $7.42.

Personalis Price Performance

The firm has a market capitalization of $748.46 million, a price-to-earnings ratio of -6.60 and a beta of 1.83. The firm has a 50 day moving average price of $5.75 and a 200-day moving average price of $5.32.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%.The company had revenue of $17.20 million for the quarter, compared to analysts' expectations of $20.12 million. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts predict that Personalis, Inc. will post -1.4 earnings per share for the current year.

Institutional Trading of Personalis

A number of hedge funds and other institutional investors have recently bought and sold shares of PSNL. China Universal Asset Management Co. Ltd. raised its stake in Personalis by 18.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company's stock valued at $62,000 after acquiring an additional 2,724 shares during the last quarter. AIGH Capital Management LLC raised its stake in Personalis by 4.5% during the 1st quarter. AIGH Capital Management LLC now owns 3,968,948 shares of the company's stock valued at $13,931,000 after acquiring an additional 169,884 shares during the last quarter. ARK Investment Management LLC raised its stake in Personalis by 6.1% during the 1st quarter. ARK Investment Management LLC now owns 7,188,197 shares of the company's stock valued at $25,231,000 after acquiring an additional 412,762 shares during the last quarter. XTX Topco Ltd raised its stake in Personalis by 147.0% during the 1st quarter. XTX Topco Ltd now owns 82,666 shares of the company's stock valued at $290,000 after acquiring an additional 49,197 shares during the last quarter. Finally, Howland Capital Management LLC raised its stake in Personalis by 7.7% during the 1st quarter. Howland Capital Management LLC now owns 282,808 shares of the company's stock valued at $993,000 after acquiring an additional 20,200 shares during the last quarter. 61.91% of the stock is currently owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.